Beyond ML Groups CEO Lan Huang On How To Bridge The Gap Between U.S. Biopharma Companies And China CROs: An Interview with PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
New York-based Beyond ML Groups provides consulting service to big pharmas, biotech companies, hedge funds and VC firms and specializes in helping them develop business strategies in China. The company also has an investment division targeting the China CRO industry. CEO and Founder Lan Huang talked to PharmAsia News' Shanghai bureau about the culture differences between China and U.S. companies and how the global financial crisis is affecting China's CRO industry.
You may also be interested in...
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required.)